@FiercePharma: Tops in FierceVaccines Thurs: Takeda appoints new vaccine development head as Novartis' Oswald heads for the door. Story | Follow @FiercePharma
@CarlyHFierce: Favorite PR of the morning so far: "The holiday stress lurking beneath the gingerbread." | Follow @CarlyHFierce
> European regulators backed continued use of Ariad's ($ARIA) leukemia drug Iclusig, albeit with strengthened warnings; the drug was briefly pulled in the U.S. last year, but put back on the market with restrictions to a small group of patients. Report
> Allergan ($AGN) paid $24 million to doctors and hospitals, the second-largest amount from any company in California, the new Open Payments database shows. Report
> Novartis ($NVS) worked out a new reimbursement deal with New Zealand to include new products for multiple sclerosis, COPD and leukemia, among others. Report
> Analysts figure that growth in drugs for heart failure will soar, largely fueled by a forthcoming treatment from Novartis. Report
Medical Device News
@FierceMedDev: Researchers implant brain-controlled prosthetic arm with sensation. Story | Follow @FierceMedDev
@VarunSaxena2: Hillary Clinton hedges on the device tax, says nation must weigh pros and cons. More | Follow @VarunSaxena2
@EmilyWFierce: $MDT sans José? Release | Follow @EmilyWFierce
@MichaelGFierce: With $RHHBY's Herceptin, green tea component doubles drug accumulation in cancer cells. Article | Follow @MichaelGFierce
> C2 Therapeutics raises $11.6M for esophageal ablation. More
> Medtronic reveals corporate shakeup pending close of Covidien deal. Story
Biotech News
@FierceBiotech: EuroBiotech Report: New U.K. biotech bags £15.5M, Forbion plans €200M fund, Serono strikes oncology deal. Report | Follow @FierceBiotech
@JohnCFierce: Regado's CEO steps down as the biotech limps forward. Story | Follow @JohnCFierce
@DamianFierce: Deal: $AUXL leaves $QLTI at the altar and accepts a $2.6B offer from $ENDP. More | Follow @DamianFierce
@EmilyMFierce: At Phila. conference, how a hospital successfully treated Ebola. Story via Philly.com | Follow @EmilyMFierce
> Prosensa heads to the FDA with its once-failed DMD treatment. Story
> Isis rolls into Phase III with an orphan drug as it waits on Biogen. More
> Novartis to shed three division heads in midst of Glaxo, Lilly deal prep. Chutes & Ladders
And Finally... Nebraska's biocontainment center is getting its first workout with the arrival of Ebola in the U.S. Report (sub. req.)